ライフサイエンスコーパス: abstinent

1 patients with alcoholic cirrhosis who remain abstinent.

2 nd experience greater difficulties remaining abstinent.

3 inning prizes increased with continuous time abstinent.

4 es when they were nicotine sated or nicotine abstinent.

5 hose cravings conflict with a goal to remain abstinent.

6 correlate with severity of use or months MA abstinent.

7 le smoking as usual and 3 days while smoking abstinent.

8 ent individuals seeking to become and remain abstinent.

9 e, whereas only one sequence was targeted in abstinents.

10 ith ARC, whereas IL-4 production prevails in abstinents.

11 day (-1.62) and a higher percentage of days abstinent (11.27%) than those who received placebo.

12 e college alcohol abusers had died, 11% were abstinent, 11% were controlled drinkers, and 59% were kn

13 core city alcohol abusers had died, 30% were abstinent, 11% were controlled drinkers, and only 28% we

14 day (-2.63) and a higher percentage of days abstinent (16.99%) than all other genotype and treatment

15 ; effect size=0.780), and percentage of days abstinent (18.18%; effect size=0.683).

16 l's RT on a Stroop task in 30 currently drug-abstinent (3 months to 2 years) MA abusers compared with

17 inks per drinking day and percentage of days abstinent, 5'-HTTLPR and rs1042173 variants interacted s

18 management (n = 157) had lower percent days abstinent (66.6) than those receiving placebo plus medic

19 to placebo in increasing percentage of days abstinent (70.10 vs 50.20; P =.02) and total days abstin

20 management (n = 309) had higher percent days abstinent (80.6, 79.2, and 77.1, respectively) than the

21 day (-1.45) and a higher percentage of days abstinent (9.65%) than all other genotype and treatment

22 ed patients with primary alcohol dependence, abstinent a median of 8 days before randomization.

23 icit memories of that experience even in the abstinent addict.

24 diction is limited by a high relapse rate in abstinent addicts.

25 nditioning is a major trigger for relapse in abstinent addicts.

26 caine craving is a major cause of relapse in abstinent addicts.

27 Similar to PBMCs in abstinents, ADH peptides induced weak T-cell proliferati

28 antigen DR, CD80, and CD86 were increased in abstinent AH patients.

29 ne abnormalities were reversed by day 360 in abstinent AH patients; however, plasma levels of tumor n

30 olled, crossover design approach was used in abstinent alcohol dependent, abstinent poly-drug depende

31 Abstinent alcohol- (n = 30) and methamphetamine-dependen

32 In this study, 131 recently abstinent alcohol-dependent outpatients were treated wit

33 hibition and underlying neural correlates in abstinent alcohol-dependent patients (AD) (n = 16) and h

34 D3 availability was compared between 16 male abstinent alcohol-dependent patients and 13 healthy non-

35 Forty-five abstinent alcohol-dependent patients in treatment and 50

36 In a double-blind randomized design, 32 abstinent alcohol-dependent patients received either bia

37 Eighty-one abstinent, alcohol-dependent patients completed a functi

38 Male (n = 18) and female (n = 10) abstinent alcoholic cirrhotic patients were studied and

39 We studied 131 recently abstinent alcoholics.

40 d similar immune responses to those who were abstinent, among both subjects with HIV/HCV and subjects

41 performed in 24 chronic marijuana users (12 abstinent and 12 active) and 19 age-, sex- and education

42 -up period of 48 weeks, 37 patients remained abstinent and 53 patients relapsed as indicated by the A

43 Non-abstinent and abstinent smokers (those abstaining for ap

44 ported drinking measures (percentage of days abstinent and drinks per drinking day) along with the la

45 ir interaction as moderators of frequency of abstinent and heavy drinking days during treatment, asse

46 lescents who have never used drugs to remain abstinent and interventions to help adolescents who are

47 t two laboratory sessions, one while smoking abstinent and one while smoking ad libitum, to assess th

48 splant drinking reported themselves as again abstinent and recommitted to sobriety when interviewed.

49 with results comparable to patients who are abstinent and those with no drug-use histories, especial

50 e of heavy drinking days, percentage of days abstinent) and plasma gamma-glutamyl transferase, an obj

51 response (ie, retained in treatment, opioid abstinent, and receiving naltrexone at the end of the st

52 oduction was lower in active drinkers versus abstinents, and IL-17 production was higher.

53 Although both extinguished and abstinent animals showed a reduction in long-term potent

54 months, and 115 (57 women) of them remained abstinent at 12 months.

55 ssation were significantly less likely to be abstinent at 4 weeks than those who preferred abrupt ces

56 re significantly more likely to be confirmed abstinent at 6-month follow-up: 21.3% versus 6.8% in the

57 more likely than those in group 1 to remain abstinent at follow-up.

58 nd 220,000 (95% CI 159,000-282,000) remained abstinent at follow-up.

59 other quit attempt among those (n = 331) not abstinent at six months was not significantly different

60 Somewhat fewer patients were abstinent at the 6-month follow-up; however, the differe

61 sessed D(2/3) availability and DA release in abstinent cannabis users compared with control subjects

62 Thirteen abstinent CD and 13 healthy participants underwent MRI s

63 or) markers of 5-HT transmission in recently abstinent chronic MDMA users compared with matched healt

64 We conducted a systematic evaluation in 72 h abstinent, chronic cannabis users (N=74) and nonusing co

65 These data suggest that in abstinent cigarette smokers, nicotine augments initial r

66 ubjective fatigue in n = 18 healthy, briefly abstinent, cigarette smokers scanned repeatedly in a pla

67 At 12 months, the annual cost per abstinent client was $16,485, $9,804, and $11,818 for th

68 roglial activation in a group of 15 recently abstinent cocaine abusers and 17 matched healthy control

69 f this observation to relapse and outcome in abstinent cocaine abusers.

70 orcement and that D2 receptor dysfunction in abstinent cocaine addicts may, in part, be determined by

71 for reducing cue-induced cocaine craving in abstinent cocaine addicts.

72 tors (PAM) may reduce cue-induced relapse in abstinent cocaine addicts.

73 tecture, and decreases daytime sleepiness in abstinent cocaine users.

74 elevation in striatal V3" values in acutely abstinent cocaine-abusing subjects relative to compariso

75 s were altered in acutely (96 hours or less) abstinent cocaine-abusing subjects, as suggested by post

76 nd neutral-relaxing-imagery conditions in 30 abstinent cocaine-dependent individuals (16 women, 14 me

77 saline infusion in three cohorts of 2-4 week abstinent cocaine-dependent participants (n = 93) and he

78 ic acid (HVA) were determined in 30 recently abstinent cocaine-dependent patients and 69 healthy comp

79 Recently abstinent cocaine-dependent patients may show dysregulat

80 f dopaminergic neurotransmission in recently abstinent cocaine-dependent patients.

81 VMAT2 availability in a group of 12 recently abstinent cocaine-dependent subjects and matched healthy

82 Fifteen healthy comparison subjects and 13 abstinent cocaine-dependent subjects underwent resting s

83 s in the varenicline group were continuously abstinent compared with 10.3% in the placebo group (OR,

84 s in the varenicline group were continuously abstinent compared with 13.2% in the placebo group (OR,

85 icipants in the gradual-cessation group were abstinent compared with 22.0% (CI, 18.0% to 26.6%) in th

86 icipants in the gradual-cessation group were abstinent compared with 49.0% (CI, 43.8% to 54.2%) in th

87 The RAI was significantly lower in the abstinent compared with the smoking satiety states (left

88 eceiving FBT (16 [39%]) were binge-and-purge abstinent compared with those receiving SPT (7 [18%]) (P

89 ate fMRI scans during both satiated and 24-h abstinent conditions, prior to engaging in a 3-week quit

90 otinized cigarette smoking conditions to the abstinent conditions.

91 1.54; F1,67 = 19.33; P < .001) and 28.8 more abstinent days (Cohen d = 0.72; 95% CI, 0.25-1.17; F1,67

92 negative urine samples (p<0.0001) and opioid-abstinent days (p<0.0001) favoured BUP-NX compared with

93 JNJ-39393406 did not increase the number of abstinent days nor reduce total smoking exposure.

94 ly reduced heavy drinking days and increased abstinent days relative to placebo.

95 f counseling to reduce drinking and increase abstinent days.

96 7 = 5.65; P = .02) and abstinence (10.0 more abstinent days; Cohen d = 0.57; 95% CI, 0.11-1.02; F1,67

97 ed patients will respond to treatment, which abstinent drug users will relapse, or which patients wil

98 In abstinent drug users, relapse is often precipitated by r

99 Persons with alcoholism who are abstinent exhibit persistent impairments in the capacity

100 ngulate cortex, regardless of the time spent abstinent (F(2,34) = 12.61; P<.001).

101 with an acute coronary syndrome (ACS) remain abstinent following discharge.

102 okers and 6 heavy smokers (>14 cigarettes/d; abstinent for >36 h).

103 king or abstinent for <6 months, and 13 were abstinent for >6 months) and hepatic mononuclear cells (

104 cirrhosis (ARC; 12 were actively drinking or abstinent for <6 months, and 13 were abstinent for >6 mo

105 6%) were abstinent for 1 week, 15 (20%) were abstinent for 1 month, 12 (16%) were abstinent for 6 mon

106 5%) were abstinent for 2 days, 20 (26%) were abstinent for 1 week, 15 (20%) were abstinent for 1 mont

107 re abstinent for 6 months, and 10 (13%) were abstinent for 1 year.

108 dividuals addicted to cocaine, 19 (25%) were abstinent for 2 days, 20 (26%) were abstinent for 1 week

109 s in the high-dose condition remained opioid-abstinent for 4 consecutive weeks, as compared with 8 (1

110 %) were abstinent for 1 month, 12 (16%) were abstinent for 6 months, and 10 (13%) were abstinent for

111 ine-dependent volunteers (16 women) who were abstinent for 7 to 10 days and 37 drug-free control volu

112 Former smokers in the control arm abstinent for 7 years had a 20% mortality reduction comp

113 icantly more negative samples, and they were abstinent for a longer period of time (5 versus 3 weeks)

114 The 105 outpatient volunteers were abstinent for a mean of 2 weeks prior to random assignme

115 3131 (29%) quit smoking and remained abstinent for at least 1 year.

116 s with multiple abstinence episodes remained abstinent for longer durations in successive episodes.

117 tors, especially because the ex-smokers were abstinent for only 25 wk on average.

118 In contrast, abstinent former METH abusers (METH(+)Tox-) receiving HA

119 At study entry, patients must have been abstinent from alcohol for 1 to 6 weeks and enrolled in

120 Smokers were abstinent from cigarette smoking for 12 hours for all se

121 Abstinence indicators (negative urines, days abstinent from cocaine during follow-up) were collected

122 consecutive weeks during which patients were abstinent from illicit opioids.

123 Thus, all subjects were abstinent from marijuana and other drugs for a minimum o

124 Case participants were abstinent from MDMA use for at least 90 days as verified

125 n opioid maintenance treatments and who were abstinent from opioids at the time of randomization.

126 Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch ther

127 s in the varenicline group were continuously abstinent from smoking compared with 17.6% in the placeb

128 atment, 461 of 784 participants (58.8%) were abstinent from smoking.

129 had end-stage liver disease and had remained abstinent from the time they were medically advised to s

130 The smokers were abstinent from tobacco for 1 1 to 17 hours.

131 nd white matter of 64 young asymptomatic and abstinent (> 5 months) cocaine users (34 male and 30 fem

132 tive therapeutic agents in the management of abstinent heroin addicts.

133 was lower (-1.53) and the percentage of days abstinent higher (9.73%) in LL compared with LS/SS indiv

134 widely used model of cue-elicited craving in abstinent human addicts.

135 cocaine, can produce craving and relapse in abstinent human substance abusers.

136 29% (n = 7), and 29% (n = 7) of participants abstinent in the 4-, 2-, and 1-week conditions, respecti

137 16% (n = 4), and 20% (n = 5) of participants abstinent in the 4-, 2-, and 1-week conditions, respecti

138 with SAMCs (n = 341) were more likely to be abstinent in the integrated care group than the independ

139 5% CI 1.09-2.07]; p=0.01) and the proportion abstinent in the past 14 days (68 [42%] vs 31 [18%]; adj

140 We noted an effect on the percentage of days abstinent in the past 14 days (adjusted mean difference

141 centage point increase in percentage of days abstinent, incremental cost per patient of avoiding heav

142 ctive cues, which can precipitate relapse in abstinent individuals.

143 ponses, urine cotinine level, number of days abstinent, lapse, and relapse were not observed between

144 tained every 6 months and use categorized as abstinent, light (1-3 drinks/week), moderate (4-7 drinks

145 ver, 100% of alcoholic patients who remained abstinent maintained long-term response, compared with 3

146 e frontal and medial cerebellar regions than abstinent marijuana users and greater usage of the reser

147 eater activation in the active compared with abstinent marijuana users demonstrates a neuroadaptive s

148 e compared with control subjects, active and abstinent marijuana users showed decreased activation in

149 The 45 abstinent MD showed patterns of insula activation during

150 Nineteen abstinent MDMA users and 21 control subjects participate

151 ferences in 5-HT transporter binding between abstinent MDMA users and participants in the control gro

152 5-HT neurotoxicity are not fully understood, abstinent MDMA users have been found to have subtle cogn

153 1.21, 3.00]; p = 0.006) and percent of days abstinent (mean percent [SD] 71.0% [38.2] versus 55.0% [

154 id withdrawal and helping patients to remain abstinent Methadone maintenance and newer approaches usi

155 The present study reports on 12 abstinent methamphetamine abusers and 12 age-, gender-,

156 Compared with controls, abstinent methamphetamine and methcathinone users had si

157 stinence (1 year to 5 years) and 16 recently abstinent methamphetamine users (1 month to 6 months) we

158 Fifteen recently abstinent methamphetamine users and 15 healthy controls

159 s were performed in 10 control subjects, six abstinent methamphetamine users, four abstinent methcath

160 imaging can be used to predict relapse among abstinent methamphetamine-dependent (MD) individuals.

161 s, six abstinent methamphetamine users, four abstinent methcathinone users, and three patients with P

162 Nicotine-abstinent mice displayed reduced locomotor activity.

163 effects of NPS are enhanced in acute ethanol abstinent mice.

164 Twelve abstinent opiate-dependent subjects listened to audiotap

165 CDS scores of those individuals who remained abstinent or drank during the trial.

166 sumed heavy use (RHU) and 29 others remained abstinent or drank minimally (treatment sustainers [TS])

167 On percentage of days abstinent or negative consequences of substance use, TEL

168 f 47) in the placebo group were continuously abstinent (OR, 3.4; 95% CI, 1.02-13.6; P = .03).

169 f 47) in the placebo group were continuously abstinent (OR, 4.6; 95% CI, 1.5-15.7; P = .004), and fro

170 Regulatory agencies are considering non-abstinent outcomes as efficacy indicators in clinical tr

171 (no CBI) had an increased percentage of days abstinent (P = .07) and a decreased percentage of heavy

172 vy drinking days (p=0.0003), 26.2% more days abstinent (p=0.0003), and a log plasma gamma-glutamyl tr

173 apse (p=0.009), and maximum consecutive days abstinent (p=0.0007), with all results best for buprenor

174 ta were acquired in the same scan session in abstinent participants with CUD before residential treat

175 Compared with sexually abstinent participants, females engaging in sexual inter

176 ntal cost-effectiveness ratio per additional abstinent patient with an SAMC in the integrated care gr

177 Additional analysis with abstinent patients as a reference showed a dose effect o

178 Non-abstinent patients had significantly higher aldosterone

179 significantly higher aldosterone levels than abstinent patients.

180 nent (70.10 vs 50.20; P =.02) and total days abstinent per study week (6.74 vs 5.92; P =.03).

181 gically primary, had persisted during a past abstinent period or was long-standing, and persisted dur

182 guished: nonusers, intermittent users during abstinent periods, intermittent users during active peri

183 ortical dopamine transmission in 21 recently abstinent persons with alcohol dependence and 21 matched

184 ach was used in abstinent alcohol dependent, abstinent poly-drug dependent and healthy control volunt

185 Sixteen recently abstinent, psychiatrically healthy cannabis-using partic

186 61-8048 prevented relapse-like behavior when abstinent rats or monkeys were reexposed to nicotine and

187 In U-50,488H-abstinent rats, the binding of [3H]MK-801 was increased

188 nsity of the shell in either extinguished or abstinent rats.

189 cb core neurons from alcohol- versus sucrose-abstinent rats.

190 of brain regions of U-50,488H-tolerant and -abstinent rats.

191 ificantly reduced when drug-experienced, but abstinent, rats are given just 5 min daily prior access

192 Divergent results across abstinent, recreationally using, and addicted population

193 ine acute influences on reward processing in abstinent, recreationally using, and addicted population

194 al responses, cotinine level, number of days abstinent, relapse, or lapse.

195 l parameters were compared between sated and abstinent scans.

196 waver in their commitment to remain tobacco abstinent should be targeted for tobacco prevention inte

197 icantly greater IQ decline relative to their abstinent siblings.

198 Overall, patients were abstinent significantly longer when receiving desipramin

199 Non-abstinent and abstinent smokers (those abstaining for approximately 12

200 orking memory task [2-back task (2BT)] in 11 abstinent smokers and 11 ex-smokers.

201 rug, placebo-controlled design, 24 overnight-abstinent smokers and 20 nonsmokers underwent approximat

202 e were 159 (77 women) biochemically verified abstinent smokers at 6 months, and 115 (57 women) of the

203 Beta2*-nAChR availability in recently abstinent smokers correlated with the days since last ci

204 long with subtle behavioral deficits, mildly abstinent smokers showed less task-induced brain activat

205 ity associated with cognitive flexibility in abstinent smokers was restored to the level of nonsmoker

206 Computational modeling indicated that abstinent smokers were biased toward response shifting a

207 After nicotine infusion, abstinent smokers with the withdrawal risk allele experi

208 awal period, which may facilitate relapse in abstinent smokers, yet the molecular neuroadaptation(s)

209 anxiety is a prominent withdrawal symptom in abstinent smokers, yet the neuroanatomical and molecular

210 own-regulated by varenicline and nicotine in abstinent smokers.

211 , suggesting higher beta2*-nAChR in recently abstinent smokers.

212 cal valuation of nondrug and drug rewards in abstinent smokers.

213 g drug-stimulus pairings specifically in the abstinent state, indicating a critical role for incentiv

214 ed reinstatement of drug-seeking behavior in abstinent subjects (models of relapse).

215 ther assessed 32 young binge drinkers and 36 abstinent subjects with alcohol use disorders.

216 Nicotine abstinent subjects, but not nicotine-naive controls, exp

217 istory-positive women were less likely to be abstinent than MDD history-negative women, but depressio

218 had significantly greater percentage of days abstinent than those receiving placebo (51.2 vs 41.6, re

219 s significantly more pleasant while nicotine abstinent than while nicotine sated.

220 7 [1.38-3.42]), and maximum consecutive days abstinent than with placebo (mean days 59 [95% CI 43-76]

221 Among the subjects who were continuously abstinent through the end of treatment, the mean absolut

222 Participants who were abstinent throughout week 7 of open-label treatment were

223 unit (beta(2)*-nAChR) are higher in recently abstinent tobacco smokers compared with participants who

224 Forty early abstinent treatment-seeking cocaine-dependent males and

225 fluid monoamine metabolite concentrations in abstinent, treatment-seeking alcoholics.

226 Recently abstinent users have been found to do poorly on neurocog

227 ormalized with duration of abstinence in the abstinent users.

228 001-January 2004 among 1383 recently alcohol-abstinent volunteers (median age, 44 years) from 11 US a

229 ual buprenorphine for 6 months or more, were abstinent while taking 8 mg/d or less of sublingual bupr

230 ing 41 patients interviewed, 21 had remained abstinent, while the other 20 had returned to some form

231 f pretransplant abstinence, 58% had remained abstinent, while the other 42% had resumed drinking.

232 pretransplant abstinence, only 30% remained abstinent, while the other 70% had resumed drinking.

233 Comparing abstinent with sated scans, smokers also exhibited signi

234 g, who had "slip" drinking, and who remained abstinent, with relapsers showing the highest scores.